Skip to main
  1. Stocks
  2. Eli Lilly
  3. Forecast
LLY

Eli Lilly (LLY) Stock Forecast & Price Target

Eli Lilly (LLY) Analyst Ratings

Based on 21 analyst ratings
Buy
Strong Buy 48%
Buy 48%
Hold 0%
Sell 5%
Strong Sell 0%

Bulls say

Eli Lilly is supported by powerful incretin franchise momentum, with Zepbound and Mounjaro driving a projected 3Q26 revenue beat and an expected guidance increase of about $2bn, while Mounjaro also continues to gain share ex-US and Zepbound volumes remain strong despite modest pricing pressure. The company’s Bridge program appears manageable, reducing Zepbound revenue by only about $132m, or roughly 2.5% of 3Q sales, while still expanding new starts and reinforcing demand elasticity. Beyond obesity and diabetes, the newly updated Inluriyo label with Verzenio strengthens the oncology pipeline, and management’s above-average sales and EPS growth outlook is backed by 2025-32 CAGR estimates of 13% and 18%, respectively.

Bears say

Eli Lilly is facing weakening fundamentals as Verzenio, Taltz, and Trulicity all missed expectations, with Trulicity TRx down over 20% y/y for the third consecutive quarter and Verzenio still hurt by pricing pressure. The company’s outlook is further clouded by MFN pricing that persists all year, mounting competitive and regulatory pressure on the GLP-1 franchise, and an expected 3Q26 EPS of $6.34 versus $9.74 consensus after a modeled $4.2bn IPR&D charge. Even with commercialization spend rising for Foundayo, the risk profile remains skewed negative because slower obesity growth, margin compression, and pipeline disappointment could materially weaken earnings power.

Eli Lilly (LLY) has been analyzed by 21 analysts, with a consensus rating of Buy. 48% of analysts recommend a Strong Buy, 48% recommend Buy, 0% suggest Holding, 5% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Eli Lilly and is not a guaranteed prediction by Public.com or investment advice.

Eli Lilly (LLY) Analyst Forecast & Price Prediction

Get the latest Eli Lilly (LLY) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Eli Lilly (LLY)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Eli Lilly (LLY) Forecast

Analysts have given Eli Lilly (LLY) a Buy based on their latest research and market trends.

According to 21 analysts, Eli Lilly (LLY) has a Buy consensus rating as of Oct 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $1,369.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $1,369.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Eli Lilly (LLY)


Eli Lilly (LLY) Analyst Forecast & Price Prediction

Get the latest Eli Lilly (LLY) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Eli Lilly (LLY)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover LLY stock data and trends